Quantcast

Latest Medical statistics Stories

2014-03-12 23:30:50

Salus IRB maintains a legacy of 28 years of continuous service coupled with expanded capabilities. Austin, Texas (PRWEB) March 12, 2014 RCRC IRB announced today that its organization has changed its name to Salus IRB. The management, administrative staff, ownership structure, and review board memberships remain unchanged. “Clinical trials are more complicated, costly, and fast-paced than ever before,” says Salus President Dwight DuBois. “Salus recognizes this changing scientific...

2014-03-11 16:26:27

Conference call to be held on Tuesday, March 11, 2014 at 4:30 p.m. Eastern Time BOTHELL, Wash. and VANCOUVER, British Columbia, March 11, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided a summary of clinical developments and anticipated near-term milestones and announced fourth quarter and year end 2013 financial results. Clinical Developments and Anticipated Near-term Milestones -- Custirsen -- The SYNERGY Phase 3 trial is designed to...

2014-03-11 08:29:47

SAN DIEGO, March 11, 2014 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) announced today that the United States Adopted Names (USAN) Council has selected "vepoloxamer" as the unique non-proprietary (generic) name for the active pharmaceutical ingredient (API) in MST-188, the Company's lead product candidate. Mast sought a unique name for its API to clearly identify it as different from non-purified poloxamers. In support of its application, the Company argued that drug...

2014-03-06 23:31:26

Connance Enhancements Meet the Growing Financial Challenges of Providers and Managing Patient Relationships Waltham, MA (PRWEB) March 06, 2014 Connance, Inc. (http://www.connance.com), a leading provider of innovative, predictive analytic-based programs that improve financial performance of healthcare enterprises, today announced the expansion of its patient-pay solution including new predictive analytics, expanded platform reporting and additional consumer engagement functionality. Since...

2014-03-04 08:32:44

CLEVELAND, March 4, 2014 /PRNewswire/ -- Parker Hannifin Corporation (NYSE: PH), the global leader in motion and control technologies, today announced that it has entered into clinical trial agreements with four of the top ranked rehabilitation institutions in the United States to support the testing and development of the Indego(®) exoskeleton. Parker is currently developing a second generation device for clinical trials starting in July 2014 to support submission for FDA approval....

2014-02-27 16:27:29

Experienced leaders form Provision Research Compliance Services, a joint venture between Schulman Associates IRB, Inc. and Falcon Consulting Group, LLC CINCINNATI and PHILADELPHIA, Feb. 27, 2014 /PRNewswire/ -- Schulman Associates IRB, Inc. and Falcon Consulting Group, LLC announced today that they have formed a joint venture, Provision Research Compliance Services. Provision offers global consultancy services for the development and implementation of Good Clinical Practice (GCP) and...

2014-02-26 08:30:01

ROTTERDAM, Netherlands and BOSTON, Feb. 26, 2014 /PRNewswire/ -- Speed, efficiency and accuracy are vital to the success of clinical trials. With large amounts of data collected and significant room for data submission errors, there is even greater potential to disqualify participating patients or expose subjects to unnecessary risky procedures due to data errors. To address these needs in clinical trials, Cardialysis, an independent Clinical Research Organization (CRO), has...

2014-02-21 12:24:22

Analysis by the Company of Phase 3 efficacy studies of Nasal Mist Technology for Dental Anesthesia expected to be complete in the next thirty days. FORT COLLINS, Colo., Feb. 21, 2014 /PRNewswire/ -- St. Renatus, LLC, announced today that the company has completed Phase 3 clinical studies and is preparing its analysis for submission to the U.S. Food and Drug Administration (FDA). The studies tested the safety and efficacy of St. Renatus' nasal mist technology in adult and pediatric...

2014-02-19 08:32:28

LONDON, Feb. 19, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: OpportunityAnalyzer: Late-Stage Chronic Kidney Disease (CKD) - Opportunity Analysis and Forecasts to 2017 OpportunityAnalyzer: Late-Stage Chronic Kidney Disease (CKD) - Opportunity Analysis and Forecasts to 2017 Summary Late-stage chronic kidney disease (CKD), encompassing stage 4 and 5 CKD, is a disease that manifests in a host of co-morbidities. Of these, bone and mineral...

2014-02-18 23:25:00

Collaboration will create methodologies to drive improved decision-making in exploratory phase development. Reston, Virginia (PRWEB) February 18, 2014 Aptiv Solutions, a global biopharmaceutical and medical device development services company leading the adoption of innovative clinical trial approaches such as adaptive design, today announced that Novartis Pharma AG, Janssen Pharmaceuticals Inc, and Eli Lilly have joined them in co-founding the ADDPLAN DF Consortium. The members of the...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related